1. Japan Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Olympus Corporation

Olympus Corporation

7733.T
Olympus CorporationJP flagTokyo Stock Exchange
1,764.00
JPY
-4.00
- -
1.94TMarket Cap
Olympus Corporation
7733.T
(Tokyo Stock Exchange)

Recent

price

1,764.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
788.27
794.84
671.45
537.12
558.58
587.74
540.97
574.88
581.3
575.51
568.25
584.7
696.16
762.94
871.54
- -
434.56
Revenue per Share
3.6
-45.88
7.24
10.26
-6.38
45.72
31.25
41.71
5.97
39.37
10.05
90.22
113.22
199.91
102.99
- -
36.31
Basic EPS, GAAP
0.79
-4.08
-2.47
29.97
18.78
-5.69
30.57
23.2
4.01
51.52
50.48
84.15
22
-18.34
109.46
- -
31.69
Free Cash Flow per Basic Share
7.54
3.75
- -
- -
- -
2.5
4.25
7
7
7.81
10
12.03
14.07
16.53
18.33
- -
- -
Dividend per Share
150.62
56.39
61.38
61.4
83.14
185.19
226.27
264.51
265.72
305.17
313.38
334.94
391.29
509.35
476.79
- -
- -
Book Value per Share
-84.12
-139.68
-20.49
118.77
129.01
135.47
164.22
200.04
199.12
151.52
127.01
176.55
270.87
399.62
416.98
- -
- -
Tangible Book Value per Share
1,075
1,068
1,108
1,328
1,369
1,369
1,369
1,368
1,366
1,312
1,286
1,283
1,267
1,213
1,144
- -
1,150
Basic Weighted Avg Shares
847,105
848,548
743,851
713,286
764,671
804,578
740,557
786,497
793,862
755,231
730,544
750,123
881,923
925,752
997,332
1,010,676
499,704
Sales/Revenue/Turnover
4.53
4.19
4.72
10.3
11.9
12.98
9.78
10.31
3.49
12.14
11.14
19.29
21.1
5.59
16.24
9.98
9.5
Operating Margin (%)
46,437
46,070
43,582
46,307
50,640
49,779
54,290
52,913
58,669
68,309
59,937
64,615
66,741
65,940
66,456
67,216
16,805
Depreciation Expense
3,866
-48,985
8,020
13,627
-8,737
62,594
42,783
57,064
8,147
51,670
12,918
115,742
143,432
242,566
117,855
68,172
41,749
Net Income, GAAP
78.37
- -
56.94
17.04
199.29
11.51
31.48
25.53
59.99
30.06
14.5
21.93
24.3
19.6
25.94
27.47
18.7
Effective Tax Rate (%)
0.46
-5.77
1.08
1.91
-1.14
7.78
5.78
7.26
1.03
6.84
1.77
15.43
16.26
26.2
11.82
6.75
8.35
Profit Margin (%)
200,762
206,165
224,177
300,206
202,735
190,941
219,297
208,371
168,521
172,937
251,682
318,354
264,465
368,645
254,192
269,434
- -
Working Capital
521,252
530,311
422,880
346,814
253,286
263,731
217,193
159,183
121,628
199,897
323,735
333,846
290,087
229,628
134,117
159,700
- -
LT Debt
115,579
48,028
151,907
331,284
357,254
366,582
396,228
444,259
442,387
371,958
395,480
511,362
641,234
757,186
751,733
812,040
- -
Total Equity
0.99
- -
2.12
8.2
-12.17
13.02
7.14
8.65
1.66
9.9
9.76
13.34
14
3.82
11.32
6.95
- -
Return on Invested Capital (%)
0.73
- -
2.06
4.09
-3.6
13.31
8.56
10.31
2.14
9.25
2.54
15.23
18.07
28.55
14.53
9.6
6.92
Return on Capital (%)
2.04
-44.12
12.51
18.23
-8.94
34.08
15.19
16.99
2.25
13.54
3.22
27.8
31
43.56
20.26
12.48
11.75
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
ST Debt
- -
114,936
- -
LT Borrowings
- -
130,546
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
1,144
- -
Market Capitalization
3,108,223
3,183,710
2,725,868

Working Capital

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
Total Current Assets
- -
657,065
- -
Cash, Cash Equivalents & STI
- -
274,891
- -
Accounts Receivable, Net
- -
166,830
- -
Inventories
- -
187,843
- -
Total Current Liabilities
- -
419,575
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
114,936
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.03%
16.02%
8.02%
Free Cash Flow
-54.96%
-187.18%
-85.5%
Net Income, GAAP
117.07%
159.09%
-42.16%
Sales/Revenue/Turnover
2.53%
6.86%
1.34%
Total Cash Common Dividend
22.73%
12.04%
7.51%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
207,723
226,608
239,070
260,496
925,752
2025
- -
239,208
- -
- -
997,332
2026
- -
247,838
- -
- -
1,010,676

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
191.9
-19.64
15.84
- -
199.91
2025
- -
29.82
- -
- -
102.99
2026
- -
18.09
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
16
- -
- -
- -
16.53
2025
- -
- -
- -
- -
18.33
2026
- -
- -
- -
- -
- -
Similar Companies
Medical Imaging Corporation (6637.TWO)
Broncus Holding Corporation (BRNHF)
QT Imaging Holdings, Inc. (QTI)
Itamar Medical Ltd. (ITMR)
NeuroPace, Inc. (NPCE)
SomnoMed Limited (SOM.AX)
Business
Olympus Corporation (7733.T), a leading global medical technology company founded in 1919 and headquartered in Tokyo, Japan, develops, manufactures and markets precision instruments primarily focused on endoscopy-enabled care, operating through Endoscopic Solutions, Therapeutic Solutions, Scientific Solutions, and Others segments; its core products encompass gastrointestinal and surgical endoscopes, endotherapy devices including energy devices and guidewires, urology and gynecology products such as cystoscopes and single-use devices, respiratory-endotherapy bronchoscopes, ear-nose-throat solutions, surgical microscopes like ORBEYE, imaging platforms including VISERA 4K UHD and EasySuite 4K systems, biological and industrial microscopes, non-destructive testing equipment, X-ray fluorescence analyzers, and biomedical materials including orthopedic equipment, serving healthcare providers, researchers and industrial customers across Japan, North America, Europe, Asia, the Middle East and Oceania. The company maintains a dominant position in minimally invasive diagnosis and treatment technologies, with recent advancements including the U.S. launch of the OLYSENSE platform featuring CADe/AI solutions, distribution partnerships with W.L. Gore & Associates for EndoTherapy expansion and MacroLux Medical for single-use urology products, CE approval for three cloud-based AI medical devices with a planned 2025 AI-powered endoscopy ecosystem rollout, acquisition of a distribution business in Chile to strengthen Latin American presence, and a comprehensive corporate strategy unveiled in November 2025 emphasizing innovation-driven growth in AI, robotics and digital ecosystems alongside organizational simplification targeting 24 billion yen in run-rate savings and a net workforce reduction of approximately 2,000 positions by fiscal 2027, complemented by leadership transitions such as Keith Boettiger's appointment as Gastrointestinal Solutions Division Head effective April 2026.